Table 2.

Characteristics of trials and sample recruitment appointments

Trial	Development of DevPICv1 N = 17			Phase 1 evaluation N = 6 (DevPICv1)						Phase 2 evaluation N = 6 (DevPICv2)
	CLASS	CHEMORAD	ProtecT	POUT		CSAW		OPTIMA		ACST II		OPTIMA		ProtecT
N appointments	6	3	8	3		2		1		2		2		2
Blinded category Appt ID:1–6				Less good 3.	Good 1. 2.	Less good 4.	Good 5.	Less good 6.	Good -	Less good 2.	Good 1.	Less good 4.	Good 3.	Less good 5.	Good 6.
Cancer (Y/N)	N	Y	Y	Y		N		Y		N		Y		Y
Surgical arm (Y/N)	Y	Y	Y	N		Y		N		Y		N		Y
N of trial arms	2	2	3	2		3		2		2		2		3
Recruiter
Surgeon	5	1	1	N/A		2		N/A		2		N/A		0
Oncologist	N/A	2	0	3		N/A		1		N/A		2		0
Nurse	1	0	7	0		0		0		0		0		2
Outcome for trial participation Yes, No or Undecideda	N = 0	N = 0	N = 5	No = 2		No = 1		N = 1		N = 0		No = 0		N = 1
	Y = 0	Y = 0	Y = 2	Y = 1		Y=0		Y=0		Yes = 1		Y = 0		Y = 1
	Undecided = 6	Undecided = 3	Undecided = 1	Undecided =0		Undecided =1		Undecided =0		Undecided = 1		Undecided =2		Undecided =0
Length of consultation	Mean:13 m 49 s Range: 8 m 58 s–16 m 22 s	Mean:30 m 46 s Range: 25 m 30s–37 m 55 s	Mean:58 m 24 s Range: 14 m 43 s–1 h 48 m 24 s	39 m 58 s 26 m 43 s 33 m 19 s		16 m 50s 24 m 01 s		31 m 10s		20 m 22 s 14 m 26 s		1 h 06 m 27 s 22 m 13 s		18 m 44 s 43 m 02 s
Length of time to rate (min)	N/A			163 m 169 m 120 m		75 m 94 m		81 m		73 m 55		51 m 54 m		39 m 65 m
Mean time to rate (min)	N/A			117 m						56 m

^aUndecided = outcome agreed was further time to consider participation and/or another appointment to discuss participation further. All participants were providing consent for themselves